|
rs121913237
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
rs121913237
|
|
|
0.740 |
GeneticVariation |
BEFREE |
In a limited validation of potentially actionable low frequency mutations, a NRAS G12D mutation in a melanoma was shown to be a false positive.
|
24885028 |
2014 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
rs121913237
|
|
|
0.740 |
GeneticVariation |
BEFREE |
To produce a mouse model of NRAS-driven melanoma, we expressed oncogenic NRAS (NRAS(G12D)) in mouse melanocytes.
|
23303902 |
2013 |
|
rs121913237
|
|
|
0.740 |
GeneticVariation |
BEFREE |
At clinically informative sites, we identified seven low-frequency point mutations (0.2%-4.7%), including BRAF p.V600E (melanoma, 0.2% alternate allele frequency), KRAS p.G12V (lung, 0.6%), JAK2 p.V617F (melanoma, colon, two lung, 0.3%-1.4%), and NRAS p.Q61R (colon, 4.7%).
|
23382536 |
2013 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
Ras mutations in human melanoma: a marker of malignant progression.
|
8120410 |
1994 |
|
rs121913237
|
|
G |
0.740 |
CausalMutation |
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs121913237
|
|
T |
0.740 |
CausalMutation |
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |
|
rs121913237
|
|
A |
0.740 |
CausalMutation |
CLINVAR |
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
|
2674680 |
1989 |